INTRODUCTION
============

Linezolid is the main oxazolidinone antibiotic in clinical use for treating serious infections caused by multidrug-resistant gram-positive organisms \[[@B1]\]. It inhibits bacterial growth by overlapping binding sites at the ribosomal peptidyl transferase center and preventing the formation of the initiation complex necessary for protein synthesis \[[@B1]\]. Point mutations in the 23S ribosomal RNA, the target site of linezolid, are the most prevalent mechanism in linezolid-resistant *Enterococcus faecalis* (LRE) isolates \[[@B2]\]. The main types of mutations include G2576T, G2447U, and G2504A \[[@B3][@B4]\]. Alterations in the conserved domains of ribosomal proteins L3 and L4, encoded by *rplC* and *rplD*, respectively, have been reported to be a less important mechanism associated with linezolid resistance (minimum inhibitory concentrations \[MICs\] of 4--8 mg/L) in enterococci \[[@B5]\].

Recently, a highly effective and transferable form of resistance related to the RNA methyltransferase chloramphenicol/florfenicol resistance (*cfr*) gene has been associated with linezolid resistance in *Enterococcus* isolates \[[@B6]\]. A second transferable resistance gene, *optrA*, from *E. faecalis* E349, described as a plasmid-borne ATP-binding cassette (ABC) transporter, has also been identified as a mediator of novel efflux-mediated mechanism of oxazolidinone and phenicol resistance \[[@B7]\]. This ABC-type transporter mediates resistance to oxazolidinones (linezolid and tedizolid) and amide alcohols (chloramphenicol and florfenicol) through ribosomal protection and could be readily transferred among enterococci \[[@B7][@B8][@B9]\].

However, these mechanisms cannot explicitly explain some non-susceptible or low-level linezolid-resistant enterococci strains (MICs of 4--16 mg/L) identified in various antimicrobial resistance surveillance programs \[[@B5][@B10][@B11][@B12]\]. At present, there is no consensus on the definition of low-level linezolid-resistance in *Enterococcus* spp., while an MIC range of 8--16 mg/L has been recommended \[[@B13]\]. A high level of drug resistance is initially defined as MIC\>64 mg/L \[[@B13]\]. Low-level resistance may serve as a stepping-stone for developing higher levels of resistance, which may lead to the evolution of hospital "superbugs" \[[@B14]\].

We investigated the molecular characteristics and mechanisms of low-level LRE isolates from the First Affiliated Hospital of Chongqing Medical University in Chongqing, southwest China.

METHODS
=======

Bacterial strain collection and antimicrobial susceptibility testing
--------------------------------------------------------------------

A total of 1,120 non-duplicated *E. faecalis* strains were retrospectively obtained in the First Affiliated Hospital of Chongqing Medical University from August 2014 to June 2017. The strains were from different samples, such as urine, secretions, blood drainage tubes, seroperitoneum, purulence, bile, and puncture fluid, and were initially identified using the VITEK2 compact and API systems (BioMérieux, Lyon, France). Antimicrobial susceptibility to linezolid, clindamycin, dalfopristin, tetracycline, erythromycin, ciprofloxacin, moxifloxacin, levofloxacin, vancomycin, ampicillin, penicillin, tigecycline, streptomycin, and gentamicin was determined using AST-GP67 cards (BioMérieux). Results were interpreted according to the CLSI guidelines \[[@B15]\]. The MICs of the LRE strains screened as described above were confirmed using the broth microdilution method, following the CLSI guidelines \[[@B16]\]. The MIC used in this study was 8--16 mg/L. The reference strain *E. faecalis* ATCC 29212 served as a quality control for the broth microdilution method. Since the experiment did not involve animals, it did not require the approval of the Institutional Review Board.

Amplification of resistance genes and sequencing
------------------------------------------------

The genomic DNA of each LRE isolate was extracted using the HiPure Bacterial DNA Kit (Magen, Guangzhou, China), according to the manufacturer\'s instructions and stored at −20℃ until use. The possible mechanisms of linezolid resistance, were screened by PCR using previously described primers and conditions: the 23S rRNA domain \[[@B17]\], ribosomal protein (L3 and L4) domain \[[@B6]\], the methyltransferase gene *cfr* \[[@B18]\], and ABC-type transporter gene *optrA* \[[@B7]\]. All positive PCR products were sequenced and blasted against the wild-type sequences from *E. faecalis* ATCC 29212 (GenBank Accession No. CP008816.1) and the complete *optrA* gene sequence from plasmid pE349 (GenBank Accession No. NG_048023.1). Nucleotide and deduced amino acid (AA) sequences were aligned using the multiple alignment algorithm in the MegAlign package (version 7.1.0; DNASTAR, Madison, WI) with Clustal W \[[@B19]\].

Molecular epidemiology investigation
------------------------------------

Multi-locus sequence typing (MLST) was performed by amplifying seven relatively conserved *E. faecalis* housekeeping genes (*gdh*, *gyd*, *pstS*, *gki*, *aroE*, *xpt*, and *yqiL*) \[[@B20]\] according to the database methodology and guidelines available at <http://pubmlst.org/efaecalis/> \[[@B20]\]. For a more detailed analysis of the different phylogeny, we used PHYLOViZ to generate goeBURST diagrams of the typed isolates. The clonal relatedness between sequence types (STs) was analyzed by PHYLOViZ against the entire *E. faecalis* database (<http://www.phyloviz.net>) \[[@B21]\]. All identified novel STs and alleles were submitted to the PubMLST database. In addition, strains with the most common ST were subjected to further pulsed-field gel electrophoresis (PFGE) analysis, as previously described \[[@B18]\], which allows for more comprehensive evolutionary comparisons.

RESULTS
=======

Antimicrobial susceptibility testing and clinical information
-------------------------------------------------------------

Among the 1,120 strains of *Enterococcus faecalis*, resistance was observed against linezolid (3.8%), clindamycin (3.8%), dalfopristin (3.8%), tetracycline (3.6%), erythromycin (3.5%), ciprofloxacin (2.3%), moxifloxacin (1.9%), and levofloxacin (2.2%). All strains were susceptible to vancomycin, ampicillin, penicillin, and tigecycline. Further, 2.1% and 2.3% exhibited high-level resistance to streptomycin and gentamicin, respectively. In total, 43 LRE strains (all exhibiting low-level resistance) were isolated with MICs of 8--16 mg/L, and 35 of these strains showed a multidrug-resistant phenotype (non-susceptibility to at least one agent in three antimicrobial categories) \[[@B22]\] ([Table 1](#T1){ref-type="table"}).

Resistance genes and sequencing results
---------------------------------------

All 43 LRE strains were positive for the *optrA* gene. Mutations in domain V of the 23S rRNA genes as well as the presence of the methyltransferase *cfr* gene were not identified in any of the strains. Comparison of the OptrA amino acid sequences of the 43 LRE strains with that of the original OptrA from *E. faecalis* E349 (designated as the wild-type) revealed that 19 strains contained three novel point mutations at positions E60K, G197D, and T285P. A novel mutation in the *rplC* gene was observed in four LRE strains; the C333T substitution resulted in an S113L change in the L3 deduced amino acid sequence. Mutation analysis of the L4 protein from 31 LRE strains identified the T35A, I98V, and N79D novel substitutions and the Q103 novel deletion ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Molecular epidemiology analysis
-------------------------------

MLST showed that the 43 LRE strains could be classified into different STs (See [Supplemental Data Table S1](#S1){ref-type="supplementary-material"}). Nine LRE strains exhibited eight novel *E. faecalis* sequence types (ST823 to ST830), and a new gki95 allele was also observed (and submitted to the PubMLST database) for the first time in China. GoeBURST analysis illustrated that none of the 43 strains exhibited clonal aggregation based on the available global datasets, suggesting that the infected cases presented were sporadic. Although MLST indicated that Strains 2, 3, 5, 8, 12, 13, 15, 21, 22, 27, 28, 33, 34, and 43 were all ST16, PFGE showed that they were of different types with 14 unique banding patterns (Lanes 1--14 represent the above-mentioned strains, respectively), indicating that MLST has a lower discriminatory ability than PFGE ([Fig. 1](#F1){ref-type="fig"}).

DISCUSSION
==========

Mutations in the central loop of domain V of the 23S rRNA gene have been considered the main mechanism of linezolid resistance among different clinical enterococci strains \[[@B2]\]. Since the first description of *cfr*-mediated linezolid resistance in an *E. faecalis* isolate (ST16) of human origin \[[@B6]\], few similar cases have been reported \[[@B7][@B18][@B23][@B24]\]. Our results did not reveal any 23S rRNA mutation sites; the presence of *cfr* seems to account for the high-level linezolid resistance by altering the drug target in linezolid-resistant strains \[[@B25][@B26]\]. However, systematic surveillance showed that low-level LRE did not possess any known resistance mechanisms \[[@B2]\]. A few studies have examined low-level resistance together with the *optrA* gene \[[@B7][@B27]\].

The *optrA* gene was recently identified in low-level LRE strains lacking the *cfr* gene or mutations in the 23S ribosomal RNA and ribosomal protein L3 \[[@B28][@B29][@B30]\]. Previously, we conducted a transcriptome analysis of LRE strains compared with a linezolid-susceptible strain; the results showed that the *optrA* gene was up-regulated in the LRE strains \[[@B31]\]. We have now presented several lines of evidence of a low-level linezolid resistance mechanism involving the *optrA* gene. Our data showed that all LRE strains harbored the *optrA* gene alone or in combination with mutations in ribosomal proteins L3 and L4. Several *optrA* gene sequence variants have been previously identified in isolates with the efflux phenotype, including the DK, ED, and KDP variants \[[@B27][@B32][@B33]\]. In our study, the 43 LRE strains exhibited novel amino acid substitutions at positions of E60K, G197D, and T285P compared with *E. faecalis* E349. These mutation sites have been previously reported in China as those likely to elevate linezolid MICs in *E. faecalis* \[[@B27][@B32]\]. Two important questions remaining are whether ABC transporter inhibitors are effective against *optrA*-positive strains and whether the presence of *optrA* can be verified by observing changes in MICs.

Another mechanism underlying linezolid resistance involves mutations in ribosomal proteins L3 and L4 \[[@B5][@B34][@B35][@B36]\]. Of the 43 LRE strains, 35 had mutations compared with *E. faecalis* ATCC-29212. Although these sequence changes resulted in amino acid changes, there were no differences in linezolid MICs among the 43 LRE strains. Previous studies have demonstrated the presence of mutations (N158S, F101L) in the L4 protein in linezolid-susceptible isolates, suggesting that some mutations may not be strongly associated with linezolid resistance \[[@B4][@B32][@B36]\]. Since these mutations did not simultaneously occur in the same strain, they appear to play a negligible role in linezolid resistance. In addition, the possibility that several mechanisms contribute to decreasing linezolid sensitivity cannot be excluded.

MLST analysis revealed that the 43 LRE strains belonged to 20 STs, and ST16 was the most common type (14/43). The epidemiological investigation showed no clonal complex correlation between these isolates, indicating that the cases in our hospital were sporadic rather an outbreak. Furthermore, MLST demonstrated eight novel STs (ST823 to ST830) and one allele (*gki95*) identified for the first time in China. These low-level LRE isolates could not be attributed to clonal dissemination, as determined by MLST and PFGE analysis. Interestingly, isolates with differently related PFGE patterns had the same ST (ST16). This indicates that PFGE is more discriminatory than MLST for homology analysis of small areas in the short term, such as the examination of hospital or ward isolates.

This study is the first to collect a large number of LRE isolates and to explore the mechanisms underlying low-level linezolid resistance in southwest China. The high prevalence of the *optrA* gene in LRE strains indicates that it may serve as a useful marker for linezolid resistance screening. Further studies are required to determine the relationship between *optrA* variants and linezolid resistance and the transmission mechanism. Furthermore, routine and persistent screening for *optrA* gene risk factors associated with the rapid occurrence and dissemination of linezolid resistance is urgently required.
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###### Supplemental Data Table S1

Epidemiological analysis of 43 linezolid-resistant *Enterococcus faecalis* strains using MLST

![Epidemiology analysis of low-level linezolid-resistant *Enterococcus faecalis* isolates by MLST and PFGE. (A) GoeBURST diagram for the MLST data set of 43 linezolid-resistant *E. faecalis* isolates. The eBURST diagram was calculated using PHYLOViZ with the goeBURST algorithm; it contains 20 unique STs for a total of 43 isolates in the database. Each circle represents one ST and the size represents the number of strains in each ST. (B) PFGE fingerprinting dendrogram and PFGE pattern of 14 linezolid-resistant ST16 *E. faecalis* strains\
Abbreviations: ST, sequence type; MLST, multi-locus sequence typing; PFGE, pulsed field gel electrophoresis.](alm-39-36-g001){#F1}

###### General characteristics and resistance mechanisms of 43 low-level linezolid-resistant *Enterococcus faecalis* isolates

![](alm-39-36-i001)

  No. Case   Date         Comorbidities                                 Samples          Wards                          Linezolid MIC (mg/L)   ST    Genetic resistance phenotype^\#^             
  ---------- ------------ --------------------------------------------- ---------------- ------------------------------ ---------------------- ----- ---------------------------------- --------- -------
  1^\*^      2014.9.13    Colon neoplasms                               Seroperitoneum   Gastrointestinal surgery ICU   16                     828   WT                                 Q103del   E60K
  2^\*^      2014.10.27   Upper gastrointestinal bleeding               Urine            ICU                            16                     16    WT                                 Q103del   E60K
  3^\*^      2014.10.28   Type 2 diabetes with multiple complications   Urine            Endocrinology                  16                     16    WT                                 Q103del   \+
  4^\*^      2014.10.29   Varicose veins of lower limb with ulcer       Ulcer tissue     Vascular surgery               16                     826   S113L                              WT        T285P
  5^\*^      2015.3.28    Cerebral infarction                           Urine            Neurology                      16                     16    WT                                 Q103del   \+
  6^\*^      2015.4.3     Cervical cancer                               Drainage tube    Gynecology                     16                     386   WT                                 I98V      \+
  7^\*^      2015.4.22    Cerebral infarction                           Urine            Neurology                      16                     714   WT                                 T35A      \+
  8          2015.6.25    Ectopic pregnancy                             Puncture fluid   Obstetrics                     16                     16    WT                                 Q103del   \+
  9^\*^      2015.7.25    Hydronephrosis                                Urine            Urology Surgery                16                     480   WT                                 WT        \+
  10^\*^     2015.8.2     Rectal cancer                                 Secretion        Gastrointestinal surgery       16                     480   WT                                 WT        \+
  11^\*^     2015.8.20    Hemoptysis                                    Urine            ICU                            8                      585   WT                                 WT        \+
  12^\*^     2015.8.24    Bladder tumor                                 Urine            Urology Surgery                16                     16    WT                                 Q103del   \+
  13^\*^     2015.10.4    Deep venous thrombosis                        Urine            ICU                            16                     16    WT                                 Q103del   \+
  14^\*^     2015.11.13   Skin infections                               Secretion        Dermatology                    16                     825   WT                                 Q103del   T285P
  15^\*^     2015.11.17   Cerebrovascular disease                       Blood            Neurology                      16                     16    WT                                 Q103del   \+
  16^\*^     2015.12.18   Gastrointestinal perforation                  Seroperitoneum   ICU                            16                     69    WT                                 T35A      T285P
  17^\*^     2015.12.20   Rectal cancer                                 Bile             Gastrointestinal surgery       8                      826   WT                                 WT        G197D
  18^\*^     2015.12.26   Cervical cancer                               Drainage tube    Gynecology                     16                     823   WT                                 N79D      E60K
  19^\*^     2015.12.27   Rectal cancer                                 Seroperitoneum   Gastrointestinal surgery       16                     631   S113L                              WT        \+
  20         2015.12.29   Bone exposed                                  Secretion        Orthopedics                    16                     631   S113L                              WT        \+
  21^\*^     2016.1.16    Cervical cancer                               Urine            Gynecology                     16                     16    WT                                 Q103del   \+
  22^\*^     2016.2.16    Intraspinal occupying lesion                  Urine            Neurosurgery                   8                      16    WT                                 Q103del   \+
  23^\*^     2016.3.7     Cervical intra-epithelial neoplasia           Drainage tube    Gynecology                     8                      632   WT                                 T35A      E60K
  24^\*^     2016.5.21    Cervical cancer                               Secretion        Gynecology                     16                     824   WT                                 T35A      T285P
  25^\*^     2016.6.8     Urinary tract infection                       Urine            Gynecology                     16                     116   WT                                 WT        \+
  26^\*^     2016.6.18    Chest tightness                               Secretion        Gastrointestinal surgery       16                     330   WT                                 WT        \+
  27         2016.7.25    Appendicitis                                  Drainage tube    Hepatobiliary Surgery          8                      16    WT                                 Q103del   \+
  28^\*^     2016.7.26    Drug poisoning                                Urine            ICU                            16                     16    WT                                 Q103del   \+
  29^\*^     2016.8.22    Sigmoid colon carcinoma                       Seroperitoneum   Gastrointestinal surgery       16                     480   WT                                 Q103del   T285P
  30         2016.8.22    Hepatolithiasis                               Secretion        Hepatobiliary Surgery          16                     830   WT                                 Q103del   \+
  31^\*^     2016.8.28    Prostatic hyperplasia                         Urine            Urology Surgery                8                      632   WT                                 T35A      T285P
  32         2016.9.3     Prostate cancer                               Urine            Geriatrics                     16                     69    WT                                 T35A      T285P
  33^\*^     2016.10.22   Urinary tract infection                       Urine            Urology Surgery                16                     16    WT                                 Q103del   \+
  34^\*^     2016.11.14   Chronic renal failure                         Urine            Nephrology                     16                     16    WT                                 Q103del   \+
  35^\*^     2016.11.21   Pelvic mass                                   Drainage tube    Gynecology                     8                      69    WT                                 T35A      T285P
  36^\*^     2016.11.24   Rectal cancer                                 Seroperitoneum   Gastrointestinal surgery       16                     823   WT                                 N79D      E60K
  37         2016.12.18   Gastric retention                             Purulence        Gastrointestinal surgery       8                      618   WT                                 WT        G197D
  38^\*^     2017.1.1     Rectal cancer                                 Drainage tube    Gastrointestinal surgery       8                      69    WT                                 T35A      T285P
  39         2017.3.31    Cholelithiasis with cholecystitis             Purulence        Hepatobiliary Surgery          8                      829   WT                                 I98V      T285P
  40^\*^     2017.4.1     Belly-ache                                    Urine            Geriatrics                     16                     585   WT                                 WT        \+
  41         2017.4.12    Colon cancer                                  Secretion        Gastrointestinal Surgery       16                     376   S113L                              WT        E60K
  42^\*^     2017.4.14    Uterine cancer                                Drainage tube    Gynecology                     8                      632   WT                                 T35A      T285P
  43^\*^     2017.5.13    Cervical cancer                               Urine            Gynecology                     16                     16    WT                                 Q103del   \+

^\*^Multi-drug resistant phenotype; ^\#^23S rRNA mutations and *cfr* gene were not detected.

Abbreviations: ICU, intensive care unit; MIC, minimum inhibitory concentration; ST, sequence type; rRNA, ribosomal RNA; WT, wild-type; T, Thr; A, Ala; P, Pro; I, Ile; V, Val; Q, Gln; S, Ser; L, Leu; E, Glu; K, Lys; N, Asn; D, Asp; G, Gly.

###### OptrA protein polymorphisms detected in 43 *optr*A-positive linezolid-resistant *Enterococcus faecalis* strains

![](alm-39-36-i002)

  OptrA variant   Mutations compared with (first-time reported) OptrAE349 from *E. faecalis* E349   Isolates (N)   Reference(s)
  --------------- --------------------------------------------------------------------------------- -------------- --------------------------------------------
  OptrAE349       No mutations                                                                      24             This study
  D               G197D                                                                             2              This study
  K               E60K                                                                              6              This study
  P               T285P                                                                             11             This study
  DD              Y176D, G393D                                                                      \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  DK              Y176D, E256K                                                                      \-             Cui et al.\[[@B32]\]
  DP              Y176D, T481P                                                                      \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  ED              K3E, Y176D                                                                        \-             Cui et al.\[[@B32]\]
  EDD             K3E, Y176D, G393D                                                                 \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  EDM             K3E, Y176D, I622M                                                                 \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  EDP             K3E, Y176D, T481P                                                                 \-             Cai et al.\[[@B27]\]
  EYDNDM          K3E, N12Y, Y176D, D247N, G393D, I622M                                             \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  KD              T112K, Y176D                                                                      \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
  KDP             T112K, Y176D, T481P                                                               \-             Cui et al.\[[@B32]\]
  RDK             I104R, Y176D, E256K                                                               \-             Cai et al.\[[@B27]\], Cui et al.\[[@B32]\]
